Table 1.

Baseline characteristics of both groups at day 0

Variables		Placebo (n = 6)	S/V (n = 7)	P‐value
Demographics	Age (months)	141.8 ± 14.11	141.1 ± 21.12	.95
	Sex (M/F; %)	(2/4)(33/67)	(3/4)(43/57)	1
Physical examination variable	Body weight (kg)	8.23 ± 1.20	8.28 ± 1.92	.97
	Heart rate (bpm)	127.7 ± 23.28	147.6 ± 21.30	.45
	SAP (mm Hg)	163.0 ± 12.47	164.4 ± 11.25	.94
	Heart murmur intensity (moderate [grade 3–4]/severe [grade 5–6]) (%)	(3/3)(50/50)	(4/3)(57/43)	.9
Medication dosage	pimobendan (mg/kg/day)	0.44 ± 0.12	0.39 ± 0.11	.57
	S/V (mg/kg/day)	NA	36.88 ±1.8	NA
Diagnostic imaging variables	VHS	11.03 ± 0.51	11.17 ± 0.41	.68
	iLVIDd	1.78 ± 0.06	1.73 ± 0.17	.65
	iLVIDs	0.75 ± 0.05	0.87 ± 0.12	.15
	LA/Ao	2.11 ± 0.16	1.85 ± 0.14	.21
	MV E Vel (m/s)	1.05 ± 0.22	0.97 ± 0.14	.58
	E/E′	12.07 ± 4.13	11.73 ± 2.35	.89
Laboratory variables	Na (mmol/L)	151.2 ± 0.91	147.7 ± 1.79	.50
	K (mmol/L)	4.41 ± 0.56	4.17 ± 0.20	.40
	BUN (mg/dL)	20.43 ± 4.99	21.59 ± 4.16	.75
	Creatinine (mg/dL)	0.65 ± 0.15	0.72 ± 0.04	.30

Abbreviations: Ao, aorta; BUN, blood urea nitrogen; E/E′, peak velocity of early diastolic transmitral flow to parietal mitral annular tissue Doppler interrogation E′ velocity ratio; iLVIDd, left ventricular internal diameter at end‐diastole indexed to body weight; K, potassium; LA, left atrium; LVIDs, left ventricular internal diameter at end‐systole indexed to body weight; MV E Vel, peak velocity of early diastolic transmitral flow; Na, sodium; S/V, sacubitril/valsartan; VHS, vertebral heart score.

Continuous variables are reported as mean and SD. Categorical variables are reported as number (%).